LSLaura Sánchez-Muñoz

Laura Sánchez-Muñoz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Sánchez-Muñoz has a total of 270 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm

    by Paula Navarro-Navarro, Carlos Maria Fernandez Gimenez, Andrés C. García-Montero, Iván Álvarez-Twose, Laura Sánchez-Muñoz, Ana Henriques, Alba Pérez-Pons, María González-Tablas, Cristina Teodosio, Maria Gonzalez, et al.

    In 5-15% of systemic mastocytosis (SM) patients, SM coexists with another associated hematological neoplasm (AHN). Most SM-AHN patients harbor a KIT-mutation, mainly KIT p.D816V, together with other AHN-related genetic alterations; however, limited data exists about the frequency and the clinical impact of the coexistence of both types of genetic alterations in the same vs. distinct bone marrow (BM) cell compartments. Here we analyzed 79 SM-AHN patients classified into cases who: i) displayed distinct unrelated genetic alterations in BM mast cells (MC) and AHN cells (21/79, 27%); ii) shared the KIT-mutation as a first genetic event (24/79, 30%) involving both BM MC and AHN cells, together with or without AHN-associated alterations restricted to the latter cells; iii) patients presenting with AHN-associated alterations as a first event (25/79, 32%) present in both BM MC and AHN cells, and; iv) patients in whom both alterations involved virtually all SM and AHN cells (9/79, 11%). Overall, patients with genetically unrelated SM and AHN more frequently showed clinical manifestations associated with SM (ie. anaphylaxis, osteoporosis and skin lesions) together with prolonged progression-free survival (PFS), while those cases with shared genetic alterations displayed signs of more advanced disease (ie. cytopenias or organomegalies) and shorter PFS and overall survival. Our findings confirm the clinical, genetic and prognostic heterogeneity of SM-AHN and point out its association with the underlying oncogenic profile of neoplastic MC and AHN cells.


  • Open Access

    Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection

    by Paula Navarro-Navarro, María González-Tablas, Alba Pérez-Pons, Laura Sánchez-Muñoz, Ana Henriques, Iván Álvarez-Twose, Paula Nafria, David Araco-Sánchez, Cristina Morales-Cabeza, Horacio Caligaris, et al.

    Detection of KIT p.D816V is a cornerstone in the diagnosis and classification of mast cell activation syndromes (MCAS) and mastocytosis. However, KIT p.D816V may be undetected due to a low mutated-cell burden in the blood and bone marrow (BM) of many patients, particularly those without skin lesions. These findings underscore the need for ultrasensitive molecular techniques for the detection of KIT p.D816V in these clinical settings. Here, we evaluated, to our knowledge, for the first time, the sensitivity and specificity of a novel Flow-SuperRCA KIT p.D816V assay, compared with conventional allele-specific oligonucleotide quantitative polymerase chain reaction (ASOqPCR), through the analysis of 548 blood and BM samples from 337 adult patients with MCAS and mastocytosis. Our results demonstrated greater sensitivity of the new technique vs ASOqPCR (limit of detection: 0.001% vs 0.01% variant allele frequency), with higher rates of positivity for KIT p.D816V in whole blood and/or BM of 64% of patients with monoclonal MCAS and 55% of patients with BM mastocytosis (P< .0001). Notably, the sensitivity of the new assay went beyond that of ASOqPCR in purified BM mast cells (P< .0001). Additionally, clonality was newly identified in 18% of patients previously diagnosed with nonclonal MCAS, who presented with a unique cutaneous MCA-related symptomatic profile. These results confirm the high specificity and ultrasensitivity of the Flow-SuperRCA assay for the detection of KIT p.D816V, emerging as a well-suited whole-blood and whole-BM test for diagnostic screening and classification of patients with MCAS and mastocytosis. These findings further highlight the clonal nature of an unprecedently high fraction of patients who presented with anaphylaxis and MCAS, with important pathogenic, diagnostic, and clinical implications.


  • Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

    by David González‐De‐Olano, Paula Navarro‐Navarro, Javier I. Muñoz‐González, Laura Sánchez‐Muñoz, Ana Henriques, Ana De‐Andrés‐Martín, Dolores Peralta‐Arjonilla, Andrea Mayado, María Jara‐Acevedo, Andrés C. García‐Montero, et al.

    Background: A close association between hereditary alpha‐tryptasemia (HAT) and mast cell (MC) disorders has been previously reported. However, the relationship between HAT and the diagnostic subtypes and clinical features of MC disorders still remains to be established.Objective: To determine the prevalence of HAT in healthy donors (HD) vs patients with different diagnostic subtypes of MC activation syndromes (MCAS) and mastocytosis, and its relationship with the clinical behavior of the disease.Methods: A total of 959 subjects were studied including 346 healthy donors (HD), 464 mastocytosis, and 149 non‐clonal MCAS patients. Molecular studies to assess the TPSAB1 genotype were performed, and data on serum baseline tryptase (sBT) and basal MC‐mediator release episodes and triggers of anaphylaxis were collected.Results: HAT was detected in 15/346 (4%) HD versus 43/149 (29%) non‐clonal MCAS and 84/464 (18%) mastocytosis cases. Among mastocytosis, HAT was more frequently found in patients with MC‐restricted KITD816V (21% vs. 10% among multilineage KITD816V patients; p = .008). Overall, median sBT was higher in cases presenting with HAT (28.9 vs. 24.5 ng/mL; p = .008), while no significant differences in sBT were observed among HAT+ mastocytosis patients depending on the presence of 1 vs. ≥2 extra copies of the α‐tryptase gene (44.1 vs. 35.2 ng/mL, p > .05). In turn, anaphylaxis was more frequently observed in HAT+ versus HAT− mastocytosis patients (76% vs. 65%; p = .018), while HAT+ and HAT− patients who did not refer anaphylaxis as the presenting symptom (n = 308) showed a similar prevalence of subsequent anaphylaxis (35% vs. 36%, respectively).Conclusion: The frequency of HAT in MC disorders varies according to the diagnostic subtype of the disease. HAT does not imply a higher risk (and severity) of anaphylaxis in mastocytosis patients in whom anaphylaxis is not part of the presenting symptoms of the disease.


  • Un hallazgo inusual. Úlcera duodenal por Giardia lamblia en un paciente asintomático.

    by Manuel Romero, Jardi Noa, Alberto Gómez, Cristina Espuche, Laura Sánchez, Miriam Alajarín, Alejandro Martínez, Juan Egea, Fernando Alberca

  • RECTORRAGIA SECUNDARIA A CRISTALES DE SEVELAMER

    by Cristina Espuche, Jardi Noa, Alberto Gómez, Cintia Bógalo, Francisco José Sánchez, Manuel Romero, Eduardo Sánchez, Luis Madrigal, Laura Sánchez, Fernando Alberca

  • Open Access

    KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

    by Paula Navarro‐Navarro, Iván Álvarez‐Twose, Alba Pérez‐Pons, Ana Henriques, Andrea Mayado, Andrés C. García‐Montero, Laura Sánchez‐Muñoz, Oscar González‐López, Almudena Matito, Carolina Caldas, et al.

    Background: Current diagnostic algorithms for systemic mastocytosis (SM) rely on the detection of KITD816V in blood to trigger subsequent bone marrow (BM) investigations.Methods: Here, we correlated the KITD816V mutational status of paired blood and BM samples from 368 adults diagnosed with mast cell activation syndrome (MCAS) and mastocytosis and determined the potential utility of investigating KITD816V in genomic DNA from blood‐purified myeloid cell populations to increase diagnostic sensitivity. In a subset of 69 patients, we further evaluated the kinetics of the KITD816V cell burden during follow‐up and its association with disease outcome.Results: Our results showed a high correlation (P < .0001) between the KITD816V mutation burden in blood and BM (74% concordant samples), but with a lower mean of KITD816V‐mutated cells in blood (P = .0004) and a high rate of discordant BM+/blood− samples particularly among clonal MCAS (73%) and BM mastocytosis (51%), but also in cutaneous mastocytosis (9%), indolent SM (15%), and well‐differentiated variants of indolent SM (7%). Purification of different compartments of blood‐derived myeloid cells was done in 28 patients who were BM mast cell (MC)+/blood− for KITD816V, revealing KITD816V‐mutated eosinophils (56%), basophils (25%), neutrophils (29%), and/or monocytes (31%) in most (61%) patients. Prognostically, the presence of ≥3.5% KITD816V‐mutated cells (P < .0001) and an unstable KITD816V mutation cell burden (P < .0001) in blood and/or BM were both associated with a significantly shortened progression‐free survival (PFS).Conclusions: These results confirm the high specificity but limited sensitivity of KITD816V analysis in whole blood for the diagnostic screening of SM and other primary MCAS, which might be overcome by assessing the mutation in blood‐purified myeloid cell populations.


  • Open Access

    Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features

    by Tiago Azenha Rama, José Mário Morgado, Ana Henriques, Luis Escribano, Iván Alvarez‐Twose, Laura Sanchez‐Muñoz, André Moreira, José Romão, Alberto Órfão, Almudena Matito

    Background: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of prostaglandin E2 and release of leukotrienes.Objectives: Here, we aimed at determining the prevalence of mast cell (MC) mediator release symptoms triggered by NSAIDs in mastocytosis patients and the associated clinical and laboratory features of the disease.Methods: Medical records from 418 adults to 223 pediatric mastocytosis patients were retrospectively reviewed. Patients were classified according to tolerance patterns to NSAIDs and other COX inhibitors (COXi) and compared for epidemiological, clinical and laboratory findings.Results: Overall, 87% of adults and 91% of pediatric patients tolerated NSAIDs and other COXi. Among adult and pediatric patients presenting DHRs, 5% and 0% reacted to multiple NSAIDs, 4% and 0.7% were single reactors, and 3% and 8% were single reactors with known tolerance to paracetamol but unknown tolerance to other COXi, respectively. Among adults, hypersensitivity to ≥2 drugs was more frequent among females (p = 0.009), patients with prior history of anaphylaxis to triggers other than NSAIDs or other COXi and Hymenoptera venom (p = 0.009), presence of baseline flushing (p = 0.02), baseline serum tryptase ≥48 ng/ml (p = 0.005) and multilineage KIT mutation (p = 0.02). In contrast, tolerance to NSAIDs and other COXi was more frequent among males (p = 0.02), in patients with anaphylaxis caused by Hymenoptera venom (p = 0.02), among individuals who had skin lesions due to mastocytosis (p = 0.01), and in cases that had no baseline pruritus (p = 0.006). Based on these parameters, a score model was designed to stratify mastocytosis patients who have never received NSAIDs or other COXi apart from paracetamol, according to their risk of DHR.Conclusions: Our results suggest that despite the frequency of MC mediator related symptoms elicited by NSAIDs and other COXi apart from paracetamol is increased among mastocytosis patients versus the general population, it is lower than previously estimated and associated with unique disease features. Patients that tolerated NSAIDs and other COXi following disease onset should keep using them. In turn, adults with unknown tolerance to such drugs and a positive score should be challenged with a preferential/selective COX‐2 inhibitor, while the remaining may be challenged with ibuprofen.


  • Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

    by Ana Henriques, Javier I. Muñoz-González, Laura Sánchez-Muñoz, Almudena Matito, Lidia Torres-Rivera, María Jara-Acevedo, Carolina Caldas, Andrea Mayado, Alba Pérez-Pons, Andrés C. García-Montero, et al.

    Circulating tumor mast cells (CTMCs) have been identified in the blood of a small number of patients with advanced systemic mastocytosis (SM). However, data are limited about their frequency and prognostic impact in patients with MC activation syndrome (MCAS), cutaneous mastocytosis (CM) and nonadvanced SM. We investigated the presence of CTMCs and MC-committed CD34+ precursors in the blood of 214 patients with MCAS, CM, or SM using highly sensitive next-generation flow cytometry. CTMCs were detected at progressively lower counts in almost all patients with advanced SM (96%) and smoldering SM (SSM; 100%), nearly half of the patients (45%) with indolent SM (ISM), and a few patients (7%) with bone marrow (BM) mastocytosis but were systematically absent in patients with CM and MCAS (P < .0001). In contrast to CTMC counts, the number of MC-committed CD34+ precursors progressively decreased from MCAS, CM, and BM mastocytosis to ISM, SSM, and advanced SM (P < .0001). Clinically, the presence (and number) of CTMCs in blood of patients with SM in general and nonadvanced SM (ISM and BM mastocytosis) in particular was associated with more adverse features of the disease, poorer-risk prognostic subgroups as defined by the International Prognostic Scoring System for advanced SM (P < .0001) and the Global Prognostic Score for mastocytosis (P < .0001), and a significantly shortened progression-free survival (P < .0001) and overall survival (P = .01). On the basis of our results, CTMCs emerge as a novel candidate biomarker of disseminated disease in SM that is strongly associated with advanced SM and poorer prognosis in patients with ISM.


  • Open Access

    Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis

    by Noelia Dasilva-Freire, Andrea Mayado, Cristina Teodosio, María Jara-Acevedo, Iván Álvarez-Twose, Almudena Matito, Laura Sánchez-Muñoz, Carolina Caldas, Ana Henriques, Javier I. Muñoz-González, et al.

    Despite recent therapeutic advances, systemic mastocytosis (SM) remains an incurable disease due to limited complete remission (CR) rates even after novel therapies. To date, no study has evaluated the expression on SM bone marrow mast cells (BMMC) of large panel of cell surface suitable for antibody-targeted therapy. In this study, we analyzed the expression profile of six cell-surface proteins for which antibody-based therapies are available, on BMMC from 166 SM patients vs. 40 controls. Overall, variable patterns of expression for the markers evaluated were observed among SM BMMC. Thus, CD22, CD30, and CD123, while expressed on BMMC from patients within every subtype of SM, showed highly variable patterns with a significant fraction of negative cases among advanced SM (aggressive SM (ASM), ASM with an associated clonal non-MC lineage disease (ASM-AHN) and MC leukemia (MCL)), 36%, 46%, and 39%, respectively. In turn, CD25 and FcεRI were found to be expressed in most cases (89% and 92%) in virtually all BMMC (median: 92% and 95%) from both indolent and advanced SM, but with lower/absent levels in a significant fraction of MC leukemia (MCL) and both in MCL and well-differentiated SM (WDSM) patients, respectively. In contrast, CD33 was the only marker expressed on all BMMC from every SM patient. Thus, CD33 emerges as the best potentially targetable cell-surface membrane marker in SM, particularly in advanced SM.


  • Impact of somatic and germline mutations on the outcome of systemic mastocytosis

    by Javier I. Muñoz-González, María Jara-Acevedo, Iván Alvarez-Twose, Jason D. Merker, Cristina Teodosio, Yanli Hou, Ana Henriques, Krishna M. Roskin, Laura Sanchez-Muñoz, Albert G. Tsai, et al.

    Systemic mastocytosis (SM) is a highly heterogeneous disease with indolent and aggressive forms, with the mechanisms leading to malignant transformation still remaining to be elucidated. Here, we investigated the presence and frequency of genetic variants in 34 SM patients with multilineal KIT D816V mutations. Initial screening was performed by targeted sequencing of 410 genes in DNA extracted from purified bone marrow cells and hair from 12 patients with nonadvanced SM and 8 patients with advanced SM, followed by whole-genome sequencing (WGS) in 4 cases. Somatic mutations were further investigated in another 14 patients with advanced SM. Despite the fact that no common mutation other than KIT D816V was found in WGS analyses, targeted next-generation sequencing identified 67 nonsynonymous genetic variants involving 39 genes. Half of the mutations were somatic (mostly multilineal), whereas the other half were germline variants. The presence of ≥1 multilineal somatic mutation involving genes other than KIT D816V, ≥3 germline variants, and ≥1 multilineal mutation in the SRSF2, ASXL1, RUNX1, and/or EZH2 genes (S/A/R/E genes), in addition to skin lesions, splenomegaly, thrombocytopenia, low hemoglobin levels, and increased alkaline phosphatase and β2-microglobulin serum levels, were associated with a poorer patient outcome. However, the presence of ≥1 multilineal mutation, particularly involving S/A/R/E genes, was the only independent predictor for progression-free survival and overall survival in our cohort. Key Points About half of the mutations other than KIT D816V identified in SM patients were germline in nature. Somatic EZH2 gene mutations provide prognostic information in addition to that of the well-established S/A/R gene panel. Visual Abstract